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Abstract
Parents of seriously ill children face difficult decisions when standard therapies are limited or
ineffective. In their search for information, they may turn to websites created by other parents
facing similar experiences. We conducted a qualitative content analysis of 21 websites created by
families with children affected by cancer or genetic disease, two serious conditions with a range of
treatment and clinical trial options. Our research questions address how parent authors portray
serious pediatric illness, available options, parties to decision making, and sources of influence. In
addition, we examine what these sites reveal about family vulnerability to various risks,
particularly the risk of misunderstanding the distinction between standard treatment and research
and the risk of overestimating the likely benefits of research participation, as well as whether
vulnerability varies by type of condition. Our results demonstrate typically favorable views on
research, but with inadequate distinctions between research and treatment and a complex set of
trade-offs in consideration of research risks and potential benefits. While portraits of vulnerability
emerge for both parents and children, so do portraits of strength and resilience. As a result, parents
describe frustration with both under- and over-protection from research participation. Our
discussion of these findings clarifies the potential for parent-authored websites to inform and
influence families considering research and treatment options for their seriously ill children.
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Parents sometimes face difficult decisions about care for their seriously ill children,
especially when standard therapies are ineffective and research participation is a
consideration. When confronted with decisions, parents increasingly turn to the Internet to
supplement, interpret, or challenge the information they receive from health care providers
(Christian, Kieffer, & Leonard, 2001). Sites created by other parents to share first-hand
experience of treatment and research options may be especially influential (Schaffer,
Kuczynski, & Skinner, 2008; Skinner & Schaffer, 2006; Han & Belcher, 2001) for some
parents. Examination of these websites provides an opportunity to understand the
experiences of parents and children in crisis, including the world of physicians, researchers,
family, and friends who accompany them on this journey. The websites are a window into
parents’ decision making, perceptions of serious family illness, and their assessments of
risks of harm and potential for benefit in both standard treatment and clinical research.
Parents motivated to create a website may differ from their readers in important ways; they
have strongly felt convictions and a willingness to share them. Yet they may also provide
valuable insight into the ways in which families may be vulnerable to various risks in the
course of identifying research and treatment options.
While the vulnerability of seriously ill children and their families is well accepted (Rossi,
Reynolds, & Nelson, 2003), the role of websites in understanding the detail and complexity
of this vulnerability is underappreciated. Our study provides an important first step in
examining these online portraits of serious pediatric illness.
Method
Our study examined 21 websites created by families with one or more minor children (living
or deceased) affected by cancer or genetic disease, two serious conditions with a range of
treatment and clinical trial options. We selected these two conditions expecting fewer
options generally for children with genetic conditions, compared to those with cancer who
are typically offered treatment in the context of research. We conducted a qualitative content
analysis of these websites to answer the following research questions:
1. How do parent authors portray serious pediatric illness and the research and
treatment options available to them? Do these portrayals differ based on type of
condition (cancer vs. genetic illness)?
2. How do parent authors portray decision making about current and future options?
Who is involved in these decisions? What sources of information are most
influential?
3. What do these sites reveal about family vulnerability to various risks, particularly
the risk of misunderstanding the distinction between standard treatment and
research, and the risk of overestimating the likely benefits of research
participation? Does vulnerability vary by type of condition?
The vivid imagery and content of sites in our sample are illustrated here by summary
presentation of two such sites, Alex’s Lemonade Stand and Nathan’s Battle. Figures 1 and 2
provide screenshots of the home pages of these two parent-authored sites.
Alex’s Lemonade Stand is a research-focused site that raises awareness and funding for
research on childhood cancer and advocates for increased enrollment of children in clinical
trials. Created by the parents of a young girl diagnosed with neuroblastoma at age 1, the site
describes their daughter’s brave and very public fight against cancer and her success in
setting up her own lemonade stands to raise money for cancer research before her death at
age 8. Honored as a heroine and role model, Alex appeared on local and national news
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programs, talk shows, and in newspaper and magazine articles. Her parents and their
supporters established the foundation and website that carry on Alex’s work.
The bulk of the site is very upbeat with bright primary colors, the lemonade theme song, and
inspirational phrases and anecdotes encouraging people to join this cause. Site contents
include a gift shop, a direct donation option, information on fundraising events, a page of
facts on childhood cancer, a journal that chronicles fundraising and grantmaking efforts, a
list of corporate sponsors, the history of the foundation, information on how to set up a
lemonade stand or related fundraising effort, links to mass media accounts of the
foundation’s work, information for children, photographs of both Alex and fundraisers
nationwide, and a children’s art showcase. A link to the family’s personal journal provides a
detailed account of the family’s efforts to save Alex’s life and the difficult choices they
faced. (The journal is hosted on another website, www.CaringBridge.org, which assists
families in creating free web pages to share information about their children’s health with
friends and family.) While the primary site presents research as an overwhelmingly positive
endeavor, the journal presents a more nuanced picture of the lived reality of participating in
clinical trials.
Nathan’s Battle is a research-focused site created by the parents of two young boys with
Late Infantile Batten Disease. Their father, Phil, launched the web site in 1998 to house all
of Nathan’s medical records: “Phil spent countless hours researching possible therapies and
diagnoses by e-mailing his records across the world. Phil and Tricia realized the importance
of being the focal point for all of Nathan’s medical records and began the battle to help
Nathan.” The site evolved to promote clinical trials involving gene transfer research (often
called gene therapy) as Nathan and his younger brother PJ participated in one round of gene
transfer research. The site documents and promotes this family’s efforts to overcome
economic and regulatory challenges to their participation in future research. Site contents
include information about the disease and related research efforts (the father’s summaries
and links to media coverage of research funded by the foundation and other research
efforts), the boys’ story, pictures of the boys, their medical records, and information about
fundraising efforts and opportunities to donate funds.
Selection Criteria
Our first goal was to identify pediatric cancers and genetic disorders best suited to our
research questions, and for which clinical trials were underway or discussed as a future
possibility. We searched the National Cancer Institute’s website (http://www.cancer.gov); a
list of conditions identified by the National Human Genome Research Institute with planned
gene transfer research trials (http://www.gemcris.od.nih.gov/); two comprehensive NIH
online directories (http://www.nci.nih.gov/cancertopics/alphalist/a-d, and
http://ghr.nlm.nih.gov/ghr/conditionsByName); databases such as BioMed Central,
eMedicine, MEDLINE, PubMed, and OVID; http://clinicaltrials.gov; and websites devoted
to specific diseases and disorders. We next conducted extensive Internet searches for parent-
authored websites that focused on these identified conditions, using popular search engines
such as Google and Yahoo, and search terms that included specific diseases (e.g., Hodgkins,
Canavan Leukodystrophy), umbrella terms for related diseases (e.g., “orphan” diseases,
“childhood cancer”), and research options (e.g., “gene therapy,” “bone marrow transplant”).
We also reviewed the websites of children’s hospitals, national foundations, and other
agencies and organizations designed to reach families affected by serious diseases.
From the resulting pool of 81 sites, we selected websites that varied by family/disease
characteristics, experimental and standard treatment options, the child’s age, and prognosis
—all factors that we expected might be related to our research questions. We included an
equal number of sites authored by families affected by childhood cancers and genetic
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diseases. We included some with children old enough to contribute to the site and/or
participate in decision making about their health care. We included sites for which the
affected child was deceased, in remission or considered cured, or was still undergoing
treatment with an unknown prognosis.
Finally, we selected sites that clearly demonstrated the family’s desire to share their
experiences with the public, evidenced by some combination of the following elements: an
explicit statement of desire for a broad audience (e.g., in a mission statement), educational
information designed to raise awareness about the disease or specific treatment or research
options, links to resources, requests for donations, invitations to sign a guestbook, and
requests that visitors spread the word about the site. Parents who author these sites often see
it as their duty not only to advocate on their child’s behalf but also to share what they have
learned with other families, and sometimes to advocate for particular options. For example,
the FightSMA website provides an educational program to transform a mother of children
affected by this genetic disease into a FighterMom, “a mother turned activist, battling ANY
serious or incurable disease or disorder affecting her child.”
To further ensure that we included only advocacy-oriented sites, we excluded websites that
required a password, visitor registration, knowledge of a specific URL, or some other tool
designed to restrict access. Although our study was identified as exempt from IRB review
given the public nature of the information reviewed, we added these criteria due to the
highly sensitive information contained in some family-authored sites.
Our sample of 21 sites is not representative of all childhood conditions or all parental
websites. After systematically surveying pediatric cancer and genetic disease conditions that
offered both standard and experimental options, we selected parent-authored websites based
on a purposive sampling strategy. We selected sites that would maximize variety along
dimensions of interest regarding parental decision making, including disease/condition,
available options, child’s age, and prognosis. Because we were especially interested in how
parents characterized the potential for benefit from research participation, we chose to
include more pro-research sites as they were more likely to discuss benefits attributed to
clinical trial participation. The sites in our sample that advocated against FDA-approved
research options provided rich data on research-related risks. Perhaps most important, we
excluded websites that did not meet our criteria for advocacy-oriented sites.
Sample Description
The final sample includes 11 sites devoted to children with pediatric cancers and 10 sites
devoted to children with genetic disorders. The age of the focal children at the time of
diagnosis ranged from 1 day to 17 years; the children’s age at the time of this analysis (or at
death) was 2.5 to 20 years. At the time of the analysis, 8 of the 21 focal children were
deceased. The time span covered by the sites ranged from 2 to 10 years, with an average
time span of 5 years. Appendix A provides a list of contents included in at least one of the
sites. Appendix B provides descriptions of all 21 websites.
Coding and Analysis
The research team initially reviewed all 21 websites in their entirety, noting portrayals of the
condition, family members and roles, decision making, and available treatment or research
options. Sites were reviewed again and coded to record an in-depth site description and
preliminary interpretations of research and treatment options. The coding form was
developed based on our research questions and refined through an iterative process of
coding and re-coding several practice websites. It includes these data categories: website;
authorship; disease and family information; authors’ goals; portrayals of research and
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treatment, including skepticism or enthusiasm about research and distinguishing it from
treatment; narrative aspects of the website, including portrayals of child, family members,
doctors, and researchers and their related roles; website components such as slogans,
metaphors, photographs, links, and appeals for donations; and general impressions of the
website, focusing on memorable aspects.
All members of the research team coded two cancer and two genetic disease websites to
refine the form and ensure coding consistency. One researcher independently coded the
remainder of the sites. A second coder provided a check on four of the remaining sites, and
the few discrepancies in coding were discussed during team meetings. A third coder
provided a check on items related to technical aspects of clinical trials across all 21 sites.
There were no important discrepancies in coding on these items. We created a data summary
matrix to compare information (including verbatim quotes from parent authors) within and
across sites, test our interpretations of the data, and draw conclusions about the depiction of
research and treatment options and related decision making. All such segments were collated
and analyzed for cross-cutting themes (Miles & Huberman, 1994). Regular team meetings
allowed for ongoing assessment of the data analysis and of the extent to which the resulting
data summary matrix enabled us to address our research questions.
Results
Portrayals of Condition and Options
CHILDHOOD CANCERS—The websites in our study clearly reflect that for most
children with cancer, clinical trials are perceived as the only option other than palliation.
Eight of the 11 cancer sites in our sample endorsed mainstream clinical trials as the only
hope for a cure, or for prolonging life until a cure is available. These online journals contain
references to multiple standard and experimental interventions; to basic research for which
they donated tissue samples; to complementary therapies such as nutritional supplements
used to mitigate the side effects of treatment and research protocols; and, in cases where the
child was near death, to palliative and hospice care. The remaining three cancer sites were
less enthusiastic about current research, sometimes critical of the FDA’s authority to permit
or prohibit certain research options, citing barriers to enrollment in existing trials, or
speculating about collusion among governmental agents, industry, and researchers to restrict
treatment options. These sites emphasized preventive options such as forgoing vaccinations
and avoiding common forms of radiation, and alternative options not approved as “first-line”
research or treatment interventions for childhood cancers. Among our 21 sites, only these
three cancer sites were skeptical, rather than enthusiastic, about mainstream research.
Portrayals of existing options often do not differentiate standard from experimental or
alternative interventions. Terms such as “treatment” and “therapy” were frequently used by
both physicians and researchers to describe clinical trials. At Alex’s Lemonade Stand and
Trinity’s Diary, Alex (neuroblastoma) and Trinity (acute lymphocytic leukemia), like some
other children in our study, obtained “compassionate release” from the FDA to use
experimental treatments outside of clinical trials. Children with very rare cancers (such as
those on the website Carly Laverty, created for a girl with mesenchymal chondrosarcoma)
were “treated” with protocols modified from different cancers or with FDA-approved
protocols tested only in adult populations. Parents were most likely to note the exact nature
of such a “treatment” if they had to apply to enter a clinical trial or to petition the FDA to
receive it.
Some parents viewed this ambiguity as a sign of medical malfeasance. At Our Alexander,
the parents explained that they had been intentionally misinformed about the nature of a
treatment that they depicted as forced on their infant son with a brain tumor. The treatment
Schaffer et al. Page 5













was offered as a new, state-of-the-art chemotherapy, but they later discovered that it had a
long history of dismal results in previous clinical trials. At Pray for Katie, the Werneckes
explained that they had received misinformation about their daughter’s options for
Hodgkin’s Lymphoma. In the course of a resulting lawsuit, Katie’s lawyer wrote:
It has recently come to the Werneckes’ attention that the treatment regimen the
State is presently forcing Katie to undergo is entirely “experimental” in nature. This
fact was never explained to the Werneckes. In fact, the prescribed treatments were
always referred to as “necessary” and the “only course of treatment available.”
Actually, the treatment is part of a Stage II clinical trial program … It is not a
proven-effective course of treatment for the treatment of Hodgkin’s disease. See
http://www.cancer.gov/clinicaltrials/CPG-AHOD00P1.
GENETIC DISORDERS—While fewer options existed for the families affected by genetic
disorders in our sample, all ten sites were very enthusiastic about research. Only one site,
The Official Alexi Soraya Site, emphasized existing treatments and late-phase clinical trials
for the affected children’s osteogenia imperfecta. The other nine sites focused primarily on
research that might lead to a cure in the future and, in some cases, some benefit for current
research subjects. Devoted to Brianna portrayed early-phase gene transfer research (GTR) as
the only potential cure for Brianna’s Canavan leukodystrophy; and Nathan’s Battle
portrayed GTR as the only potential cure for Nathan and brother PJ’s Late Infantile Batten
Disease. At Hope for Henry, the parents of a young child affected with Fanconi’s Anemia
described how they “pushed the envelope” by pursuing nine rounds of in vitro fertilization
with pre-implantation genetic diagnosis (IVF-PGD), hoping to produce a non-affected,
genetically matched sibling to allow a second bone marrow transplant for Henry. At the
same time, they advocated for and described their collaboration with scientists on
international research that might lead to future treatments.
While families affected by genetic disorders typically adopt a future-oriented focus on
research and use terms such as “clinical trial” and “translational research” when explaining
their decisions, they also blur the boundary between research and treatment by
characterizing current research interventions as treatment. For example, Brianna’s mother
(speaking as Brianna) describes GTR as “the research I’m in to save my life.” Nathan’s and
PJ’s parents describe GTR as a potential “life-saving treatment.” At Charley’s Fund, his
mother, after explaining that the current, non-curative treatment options for Duchenne
Muscular Dystrophy are extremely limited and entail serious side effects, looks forward in
this way:
Because there is so little scientific data on the disease, we have been seeking out
doctors who suggest treatments that they “have a hunch” might help based on
anecdotal evidence. Although this is a scary basis for medical decisions, we have
no choice but to take a chance on [them] until there is more empirical evidence on
which we can rely … [Explaining their focus on future experimental therapies:]
“It’s so important—and therapeutic—for us to focus on the potential of the future.
So we don’t usually go into detail about how Duchenne is affecting Charley every
day of his life.
Despite such statements, these parents and others who anticipated future benefits from
present genetic research tended to be much clearer than the parents of children with cancer
about the differences between research and treatment. These parents were very specific
about advocating for research, often discussing a need to streamline the FDA approval
process necessary to move laboratory research to human trials, and sometimes on to
standard treatment with the larger population of affected children. However, just as with the
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cancer sites, when clinical trials were available, parents tended to blur the research-treatment
distinction.
Decision Making for Children with Serious Conditions
The parents who author these sites chronicle their difficult decisions regarding treatment and
research options for their child. The decision making is portrayed as a confusing, unwieldy
process of weighing both scientific and experiential knowledge. Parents gather and manage
information, seek second opinions and legal counsel, interpret research, monitor their child’s
signs of deterioration or improvement, and ultimately serve as final arbiter among many
voices.
INDIVIDUALS INVOLVED IN DECISION MAKING—As the following examples
illustrate, parents, children, physicians, and state and federal officials occupied different and
sometimes unexpected roles, varying by site and over time.
On Alex’s Lemonade Stand, the focal child occupied the roles of monitor and interpreter of
signs/symptoms, along with her parents and doctors, during certain stages of her treatment:
“She is so aware of her body that she actually told Dr. Maris last week, after a delay in
starting her chemo due to her poor counts, that she needed to start her Temador
[chemotherapy agent] to feel better. So, despite her poor counts, we started her on her
chemo and of course, it did make her feel better in some ways.” Earlier in their quest for
treatment, Alex’s parents attributed great interpretive power to her oncologists and great
respect for her activism:
We came here then thinking we were coming for a one time treatment—something
to relieve her pain and give her “more time.”… The fact that her cancer was
reduced so much by the high dose MIBG [radiotherapy] led to the recommendation
by her oncologists to pursue more aggressive treatments. I would not have
imagined that four years later our lives would still be so consumed by her hospital
visits and her future would still be so uncertain.… I also never would have guessed
that Alex would become such a successful activist for childhood cancer.
At Valerie Grace, the parents of a young girl with a rare brain tumor occupy the role of final
arbiter. Despite their self-described “anti-medicine” stance, they view the chemotherapy as
the way to follow God’s word:
Two studies I looked at of pilomyxoid astrocytomas (the only ones I could find)
showed more deaths of children who did chemo than children who chose no
treatment.… The studies included a very small sample of children, and I know that
God does not work off statistics. However, the studies seem to support the choice
we are making. [And later] I can’t believe we are doing the chemo! We always said
noway. But we prayed (and prayed, and are praying) and really hear God saying
yes.
Three other sites detailed how the FDA, child protective services, foster parents, the courts,
and/or biomedical professionals took over the role of final decision maker when the parents
expressed concern about or resistance to the prescribed course of treatment or research
intervention (i.e., chemotherapy and/or radiation). Only one of these sites, Pray for Katie,
documented a family’s success in challenging state intervention in decision making about
treatment and research options.
CRITICAL ROLE OF RELATIONSHIPS WITH PHYSICIAN RESEARCHERS—
Parents who were enthusiastic about biomedicine typically described powerful relationships
with physicians and/or researchers. Henry’s family depicted an intimate relationship with
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researchers and described a lab in which photos of Henry were hung on the wall by
researchers working on “his” cure. In her blog, Charley’s mother included a letter she
received from a scientist working with her son’s tissue samples, suggesting a strong personal
commitment to curing Charley’s degenerative disease, and the power of a parent-authored
website to serve as a catalyst for scientific research:
I took the liberty of checking out the web-page for Charley’s Fund and was quite
touched by your predicament. I have 2 boys of my own and, given the situation, it
struck me quite hard that time is not on our side if we are to help him. I don’t care
about the funds at this point … I initiated the project today. I have assigned my best
technician to make the gene targeting vector (though we will all pitch in). After I
described the problem to him, he was overwhelmed with honor at being asked to
pursue such a noble endeavor. I can personally assure you that, of everyone I know,
he is the person who can make this vector as fast as is humanly possible. It is a
fairly complicated gene modification to make … Today, I designed the vector and
we are on the move … Anyway, I just wanted to let you know that there will be no
more delays. Charley and many other children are too important for me to wait any
longer.
In her blog, Alex’s mother reveals her faith in her daughter’s doctor, who had advised
participation in numerous clinical trials over the course of Alex’s illness:
Dr. Maris and we have given this a lot of thought and we all feel that she has the
potential to benefit from this study, and there is not a high risk to her overall health
(although there is obviously some degree of unknown and known risks in any
study) … Dr. Maris has always taken the “big picture” into account when treating
Alex and we know that he would not recommend switching her to something that
he did not feel had real potential to benefit her.
Thus, while these parents typically conducted their own research and attempted to find
support for their doctors’ recommendations, they were often persuaded to consider specific
options in the context of trusting relationships with physician and/or researchers.
On the other hand, families who lacked these close ties to and great trust in biomedical
professionals, either due to general skepticism or past experiences, tended to seek second
opinions and/or challenge the recommendations made by their child’s physician. Based in
part on their negative experiences with specialists, hospitals, and Texas Child Protective
Services, Katie’s parents resorted to the court system to fight their oncologists’
recommendations. Daniella Rogers’s father stated that while he initially believed that his
daughter would get the best possible care for her rhabdomyosarcoma within a clinical trial,
he later learned that the doctors had misled him by equating it to the best standard care
available. Once he became aware of their errors, he identified hospitals that provided
different treatment and research options and asked to move Daniella to one of them, but it
was too late. He believed that her doctors failed to report negative outcomes in their
research; did not monitor his daughter for signs of known, potentially fatal side effects;
failed to diagnose the disease that finally killed her; and then changed her medical records to
cover their tracks. He wrote:
Our mission in life is to help parents of children, and anyone who takes part in
research.… There are millions of more dollars dedicated to the recruitment of
children into research than with anyone else. We want parents to know that they do
have choices in their child’s treatment. We hope you will take the time to look over
[this] site and educate yourself.… Please be aware that when you take your child to
a teaching hospital you will need to educate yourself on which treatments are
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“standard of care,” and which ones are not. Need help deciding? Please email us
with your concerns.
Portrayal of Risks and Benefits of Options
HOW INFORMATION IS PORTRAYED—The sites in our sample offer an extraordinary
variety of source materials on risks and benefits, including what parents learned from
conversations with physicians or other parents, the parents’ online research, their
observations of how their children reacted to various options, and quotes from children
about how an option makes them feel or their hopes for a future option. Parents provide
many links to other information, such as research articles; websites for hospitals, individual
physicians/researchers, foundations, and support groups; and mass media reports on research
advances or exposés. For some sites, home pages and fundraising pages focus solely or
primarily on potential benefits, and information on risk is buried in the narratives contained
in personal journal pages. Other sites have entire pages devoted to risks and benefits, with
consent forms, clinical trials information, and copies of physicians’ notes and medical
records.
All sites include information on the benefits of at least some of the standard and
experimental options they discussed. The range of anticipated benefits included curing the
child, prolonging the child’s life, reducing pain/discomfort or specific symptoms, improving
the child’s (and the family’s) quality of life, and improving treatment options for all/future
children. Benefits were sometimes discussed with great specificity (e.g., expected reduction
in tumor size), while at other times they were vague (e.g., “keeping hope alive”). “No
change” is explained as a benefit as Nathan’s family describes their research experience:
Nathan goes to NYC to have his 6 month evaluation performed. This evaluation
includes a MRI and MRS [medical imaging and measures of metabolites] to better
help evaluate the effects of the treatment.… Nathan’s MRI shows No Change!
Again, given the goals of the treatment to stop the progression of the disease, no
change is a POSITIVE result, meaning if the brain doesn’t show more degradation
then the therapy may be working.
While all of the childhood cancer sites included risk information, only two of the genetic
sites did so. This split corresponded to differences in the availability or immediacy of the
option under consideration. Risks of harm were broad in scope: pain, suffering, or
debilitation during the course of treatment or trial participation; possible ineligibility for
future trials; burdens on siblings, parents, and other family members; and long-term effects,
such as risks of later cancers attributed to current treatment. As Valerie Grace’s mother
reflects on the decisions made to treat their daughter’s rare brain tumor, she imparts lessons
her family has learned about social harms, such as harsh judgments by others for their
decisions:
We have learned a lot this year, but I have been tested in big ways over the past few
months when it comes to relationships. In part, from being isolated and feeling
lonely at times—in part from hearing from people that we are making the wrong
decisions/or that we waited too long to start the chemo. But I know that we have
done things just as God has called us to, and truly have no regrets (other than the
way I feel when I hear such things).
AUTHORS’ REASONS FOR PRESENTING RISK AND BENEFIT INFORMATION
—Parents provide risk and benefit information for a variety of reasons. Some, for example,
do so specifically to educate website visitors seeking information about available options or
to encourage financial support either for related research or for their child. Others include
this information in the course of explaining the decisions they have made or in critiquing
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decisions made for them by doctors, state agencies, and others. In two of the three skeptic
sites, parents offered copies of both “bad” consent forms that had misled them and “good”
consent forms, obtained from other sources, that the parents felt offered better descriptions
of risks and benefits. They also included graphic descriptions of the negative outcomes of
certain “treatments,” which they felt should have been emphasized as likely risks of that
option.
Detailed family sagas may accompany descriptions of benefits sought. Nathan’s parents
describe their fight to obtain GTR for their two sons with a timeline of events and entries
dealing specifically with the potential benefits of GTR for their sons. They link observed
outcomes in laboratory mice to potential outcomes in humans (“it will work”), and they
describe the positive outcomes of their sons’ involvement in research as reasons to push the
FDA to move faster in approving new clinical trials involving humans. Likewise, Brianna’s
mother uses several types of benefit information in her appeal for inclusion in GTR clinical
trials for her daughter’s degenerative genetic condition:
Gene therapy has grown in the past year. Our first treatment was a Liposomal
Vector injected through a shunt in the top of the head, and only penetrated what it
hit. Now, with all the new technology, our next treatment, which is currently
awaiting FDA approval, is going to be a Viral Vector, which is to be a thousand
times stronger than the first one. With this, the doctors are going to drill 6 tiny little
holes at the pin point areas of the brain and through that they will inject the new
gene. It has been said that with the proper therapy and rehabilitation afterward they
do not see why they would not be walking. Of course this is experimental and that
is not a definite but it is a bigger hope for those families involved. Brianna’s first
treatment was done in March of 1998. Before the operation she was considered
legally blind, glasses would not help. She had very little head control and her
muscles were very tight. Since the operation she has had no further deterioration in
the white matter of the brain, which is what this disease affects. She has glasses
now and can see 4–5 feet in front of her. She can lay on her stomach and lift her
head up, she is not tight fisted any more, and is much happier, it seems. I feel that if
the first treatment can do all this, just picture what the next one will do.
COMPLEX TRADE-OFFS—Parents depict complex trade-offs among a broad array of
potential benefits, risks, and burdens with striking regularity. Some caution about the trade-
offs between the short and long-term effects of their choices. Joshua’s mother, for example,
wrote at Joshua’s Journal regarding her son’s Ewing’s Sarcoma:
Now, our options [after relapse] are not good ones as we have to accept the fact that
we have to do everything possible to stop this monster, which could mean some
long-term side effects that we hoped not to have to face.… I pray he will
understand as much as possible at his young age that we have no choice right now.
Similarly, Alex’s parents view each round of chemotherapy leaving Alex weaker than the
last, as a desperate cycle, until she will no longer be eligible for particularly promising
clinical trials should they arrive during her lifetime. Focused on the short-term benefits she
observes, Brianna’s mother fights for repeated participation in GTR, until doctors tell her
that Brianna is no longer likely to benefit from them due to advanced brain deterioration.
Paradoxically, a child’s current good health may complicate decisions, as the same signs of
“good health” can hold opposite meanings for families with different goals. Alex’s mother
stated that the stronger Alex was going into a study, the better she was likely to do. In
contrast, Katie’s family wanted to stop tumor growth with minimal medical intervention.
Her parents decided that when Katie was in good health, they would choose not to try
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anything new. In his blog, Henry’s father covers the gamut of difficult issues raised in many
sites:
Though everyone in the family is itching to go home, I am worried about leaving
too soon.… I really want those few good weeks of nutrition, no pain, stable counts,
but laurie, understandably, doesn’t believe that is going to happen any time soon
and thinks henry will be better off at home. Sometimes I think she is the champion
of “quality” of life, while I stick crazily to this notion of “quantity” of life. But it
really isn’t that simple. I think that we often get to the point where we’ve had just
too much of the hospital and all of the associated dehumanizing nonsense and get
greedy for home. And we think that the more we’re away the harder it is for henry
to get better because his emotional well-being has such a strong connection to his
physical recovery. But often we rush home only to turn back around a day or a
week or a month later for the hospital.
Henry’s mother, Laurie, also reflected on quality-of-life issues, including concerns about the
long-term side effects of standard and experimental options and the IVF-PGD:
More than 175 shots, 97 eggs and four potential, but failed, pregnancies later, we
were really no closer to saving Henry’s life than we were 18 months ago when we
took our first step down this path. We could now officially say that we had done
everything we could to help Henry. But that was little solace. We wanted to save
his life.
Discussion
In the websites they create, parents of seriously ill children portray the experience of serious
pediatric illness, treatment, and research with extraordinary depth. They demonstrate that
decisions about treatment and research are complex and deeply embedded social processes,
involving an extended network of influences often not obvious to the health professionals
caring for sick children or government regulators who oversee their research participation.
They reveal a remarkably broad sweep of actors, including parties as diverse as the child,
other parents, alternative medicine websites, the FDA, child protective services, and the
court system. The sites describe ongoing dialogues between parents and numerous medical
professionals and scientists. At times, it is the ill child’s embodied experience of the disease
that influences a decision; at other times, remote governmental forces intervene, forcing or
barring participation in a particular treatment option.
The websites also reveal the multi-dimensional nature of vulnerability for those coping with
serious childhood illness. Parents are vulnerable both to misunderstanding the distinction
between research and treatment and to misunderstanding and overestimating the potential of
medical research to benefit their children. While the goal of treatment is benefit for an
individual patient, the goal of research is production of knowledge that contributes to future
patient care, regardless of whether or not subjects in a clinical trial benefit from the study
intervention or from other aspects of their participation. The tendency to misunderstand the
distinction between research and treatment, a phenomenon called “therapeutic
misconception,” has been observed in many studies (Appelbaum, Roth, & Lidz, 1982;
Daugherty et al., 1995; Joffe 2001; Henderson et al., 2006; Henderson et al., 2007).
Careful attention to the distinction between treatment and research is particularly important
in pediatric trials for two reasons. Federal research regulations (U.S. Department of Health
and Human Services, 2005) identify children, by definition, as a vulnerable population in
need of special protection from the potential risks of research. Risk and benefit in pediatric
research are framed differently than in adult research, requiring clearer proof of benefit in
relationship to anticipated harms. As a result, children have been excluded from
Schaffer et al. Page 11













participation in very risky research with little or no prospect of medical benefit. The parent
authors of three cancer sites—Our Alexander, Pray for Katie, and Daniella Rogers—vividly
portray the risks of research participation; such sites may offer evidence of the need for
these higher standards and for children’s exclusion from clinical trials in which potential
risks outweigh benefits.
At the same time, some view this higher threshold of protection as a detriment, preventing
the advances in pediatric care they associate with cutting-edge or very risky research. The
anguish conveyed by the parents of Brianna, Nathan, Charley, and others attest to these
concerns. Such pediatric research has strong support in Team Mat and FightSMA, as in the
financially successful Alex’s Lemonade Stand. Motivated to act in the best interests of their
children, these parents often see research participation itself as a benefit. Physician
researchers are also motivated by beneficence to offer—and, as illustrated in Charley’s Fund
and Hope for Henry, even to develop—experimental interventions.
Thus, strong tensions emerge when choices for seriously ill children seem both few and
dangerous. Parents claim vulnerability both when they are not protected enough from
zealous researchers or from misunderstanding the likely results of research participation and
when their children are excluded from clinical trials that they believe might prove beneficial.
We found that both forms of vulnerability were factors across both cancer and genetics sites.
Pediatric cancer websites tended to present research as a treatment option. The anger and
disillusionment resulting from research participation on some of these websites (e.g.,
Daniella Rogers) demonstrates that some parents were all too aware of their vulnerability to
therapeutic misconception. At the same time, cancer sites such as Alex’s Lemonade Stand
focused on the vulnerability to reduced options due to a lack of financial investment in
pediatric trials. The genetics sites, with few treatment options, more clearly depicted the
context of research and expressed hope that future studies might include or benefit their
children. However, when clinical trials were currently available for these children, parents
described them as treatment options in the same ways observed among the cancer sites.
Moreover, their focus on future research highlighted their vulnerability to a lack of options,
hence their fight to hasten FDA approval of experimental options.
Parent-authored websites have additional messages about vulnerability for their readers.
Sites such as FighterMom focus on vulnerability related to lack of understanding, assuming
that knowledge is power. Parents want to help people become powerful by offering both
information about treatment options and their risks and benefits, as well as descriptions of
their own extensive research and networking with others. For the 14 research-focused
fundraising sites such as Alex’s Lemonade Stand and Nathan’s Battle, vulnerability results
from a lack of financial support, either for research generally or for a particular child’s
participation in research. Parents also endure an everyday vulnerability that has little to do
with specialized knowledge or research support. Instead, this vulnerability concerns a set of
wrenching tradeoffs. Parents look for hope, for more options, and for a quality of life; they
chronicle these related odysseys in detail. At the same time, they are cautious about the
range of personal, family, and medical risks that are attached to their quests. These risks are
often poignantly illustrated in journal entries, such as those by the parents of Alex and
Henry. We found that parents may feel more vulnerable to influences when their child’s
view of ongoing treatment or research participation differs from their own or those of their
doctors, as well as when they lacked strong relationships with clinicians and researchers.
Vulnerability, then, was a matter of perspective, based on the particular lived experiences of
illness, medical care, and research.
The Internet offers revolutionary opportunities for information-sharing and advocacy such
that parent-authored websites may transform family decision making into a public activity
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with the potential to influence the decisions of other vulnerable families worldwide.
Advocacy-oriented sites such as those in our sample are particularly useful cases for
understanding the processes involved in parental decision making and the sources of their
vulnerability. These sites provide extensive information on research and treatment options.
They tend to use highly persuasive language and imagery that was intended to be influential
for parent visitors. Lastly, because of their links to major gateways, inclusion in search
indexes, and frequent coverage in the mass media, parental sites with explicit outreach
missions are likely stops for parents seeking information and/or support online.
The importance and influence of parent-authored sites is underappreciated by clinicians and
researchers. In contrast to sites created by institutions or professional organizations, these
sites provide a rich portrait of the lived experience of decision making and choices for
families with seriously ill children. These sites offer insights into the sources of influence on
families with seriously ill children, and how these influences affect decision making. They
also demonstrate how easy it is to underestimate parental resourcefulness and sources of
strength, showing us that at times, vulnerability is a reductive and misleading label. Finally,
and perhaps most importantly, these sites are written by, and intended to help, people of
varying backgrounds and skills, reaching across class and educational barriers. We must not
fail to appreciate the influence that parent sites may have on other families faced with
similarly difficult, important, and tragic choices.
Best Practices
In offering treatment or research participation to parents of seriously ill children, it is often
important to understand the sources of information parents find helpful for their decision
making. While researchers and clinicians may view parent-authored websites as potentially
misleading sources of medical information, they should consider more than the accuracy of
the medical information in their assessment. These sites are also powerful sources of
information on perceptions of parental roles, on how and where parents should seek
information, and on similarities or differences between research participation and treatment.
Rather than dismiss parent-authored sites, researchers and clinicians should ask parents
where they have sought information and what they found useful. Such an assessment may
help researchers and clinicians bridge potential gaps in understanding treatment or research
options, in aligning goals in the child’s best interests, and in respecting the preferences and
values of the family. An understanding of these influences may help researchers and
clinicians address the complex concerns and needs raised by this illness experience.
Research Agenda
Little if any research has described the content of parent-authored websites as we have in
this paper. Still less has focused on the impact of such websites on families who are seeking
help in making decisions about their seriously ill children. We need a better understanding
of this growing phenomenon. And because these sites sometimes share a relationship with
websites such as CaringBridge, which aim to offer families a protected web space to share
communications regarding ill family members, their goals and expectations of privacy
should also be examined. Finally, because we restricted our sample to those websites with
an explicit advocacy agenda, there are many sites—possibly quite influential—that were
excluded from our analysis. A more systematic sample of all such websites is an important
next step for research that examines influences on parents making decisions. Such an
exploration may provide valuable teaching tools for future clinical researchers and provide
insight to government agencies conducting studies or regulating products about how to
better communicate with parents and be transparent about conduct and oversight of clinical
trials. Of particular interest may be the close relationship between some families and the
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researchers that may undermine scientific independence and voluntary participation in
clinical research. To give just one example, the NIH Recombinant DNA Advisory
Committee raised concerns about the research in which Nathan and his brother were
enrolled, after some subjects died. As a result, the principal investigator wrote an article
addressing the challenges of conducting research funded by patient advocacy groups,
including the need to avoid both undue pressure on investigators and institutions, and the
therapeutic misconception. (Arkin et al., 2005)
Educational Implications
Our results have implications for clinicians, researchers, and IRB members who should
become familiar with parent-authored websites as a tool for parent communication and
education. For clinicians, because the web content is highly accessible to families from
different educational and cultural backgrounds, it offers examples of how families
experience serious childhood illnesses and their perceptions of parental and child roles. For
researchers and IRB members, website content often advocates for (or more rarely, against)
research participation. Thus, their portrayal of research goals or the guidance they offer
families is instructive in both reviewing research protocols and in informed consent
discussions with families. For everyone, the multifaceted nature of vulnerability portrayed in
the websites teaches us about the resourcefulness and complex concerns of families faced
with serious illness.
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APPENDIX A
Website Contents.
• Child’s story (illness narrative)
• Parent journal/blog/updates
• Pictures/images (e.g., of child, family, researchers, laboratories, hospitals, angels)
• Videos/slideshows/music/other multimedia
• Information about disease/disorder
• Fundraising information or tools, online gift stores, etc.
• Information sources used by parents or recommended to visitors
• Contact information
• Information on helpful organizations, support groups, etc.
• Scientific articles, books, other documents (on the site or hyperlinked)
• Links to mass media coverage of research options and/or related ethical issues
• Information on (and correspondence with) doctors
• References to religion/spirituality
• Guestbook, message board, blog comments, etc.
• Medical records, treatment results, etc.
• Media coverage of child
• Grant information (awarded by foundation sites)
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• Medical term glossary
• Information about other affected children
• Explicit advice about standard and experimental treatment
• FDA information/laws/regulations/informed consent documents/legal testimony regarding options and
parents’ rights
APPENDIX B
Descriptions of the 21 Websites.
Site Name Diagnosis and Age Function/Mission of Site
Cancer Sites
Our Alexander Diagnosed at age 2 with a
brain tumor; died at age 2-½
Informational site set up to memorialize son who died
while on a court-mandated chemotherapy protocol and
to warn other families about the dangers of “standard”
treatments, including vaccinations and FDA-approved
chemotherapies. They hoped to change federal policies
to increase parental control over their children’s health
care; to decrease the power of dishonest, profit-driven
researchers and medical establishments; and to advocate
for informed consent and alternative treatments.
Daniella Rogers Diagnosed at age 1 with
Rhabdomyosarcoma; died at
age 5
Informational site set up after daughter died to warn
families about the dangers of FDA-approved clinical
research. They advocate for informed consent and
hope to raise awareness about this type of cancer and
the full range of treatment and research options.
Pray for Katie Diagnosed at age 13 with
Hodgkins Disease; now age
14
Informational blog set up to promote prayer for Katie
and to share updates on Katie’s health with family and
friends. The blog evolved into an advocacy site through
which her father, mother, and Katie herself raised
awareness about their battle against “state-sponsored
medical terrorism.” They also sought financial, legal,
and medical assistance from their readership.
Alex’s Lemonade Stand Diagnosed at age 1 with
Neuroblastoma; died at age 8
Research-focused site set up to raise awareness about
and funding for pediatric oncology research. Through
their foundation, Alex and her parents advocated for
child enrollment in research and provided grants to
support pediatric clinical trials. The site also includes a
link to the family’s CaringBridge journal.
Trinity’s Diary Diagnosed at age 2 with
Acute Lymphocytic
Leukemia; died at age 3
Fundraising site set up to raise money to cover their
own health care costs and then, after her death, as a trust
fund to provide palliative and hospice care, and to
support AML families in financial crisis. The site also
contained informational updates for family and friends;
detailed information about complementary nutrition,
palliation, and hospice services; and a memorial to
Trinity.
Carly Laverty Diagnosed at age 4 with
Mesenchymal
Chondrosarcoma; now age 7
Informational website set up to provide updates for
family and friends; to raise awareness about the disease;
to advocate for research and treatment funding; and
to raise money to support families of children with
serious illnesses.
Caleb’s Cancer Pages Diagnosed at age 10 months
with Hepatoblastoma; died at
age 2
Informational site set up to provide updates for family
and friends; to share information with other affected
families; to raise awareness about this type of cancer;
and to share information about fundraisers that support
research.
Matthew’s Page Diagnosed at age 1 with
Wilm’s Tumor; now age 11
Informational site set up to share updates with friends
and family, and to advocate for pediatric research.
Joshua’s Journal Diagnosed at age 4 with
Ewing’s Sarcoma; now age 8
Informational site set up to share updates with friends
and family. It contains a link to an affiliated support-
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Site Name Diagnosis and Age Function/Mission of Site
focused foundation site that provides information and
referrals; information management tools; social support/
networking among affected families; and opportunities
to raise funds for CureSearch research/advocacy.
Valerie Grace Diagnosed at age 10 months
with Pilomyxoid
Astrocytoma of the optic
chiasm/hypothalamic area;
now age 2-½
Informational site set up to share their experiences and
research with other families, and to share information
about existing and planned research studies.
Teens Living With
Cancer
Diagnosed at age 17 with
Myelodysplastic Syndrome;
died at age 19
Information and support-focused foundation site set
up to raise awareness about cancer and issues facing
teens with cancer; to advocate for research and
support services; to raise funds online support services
and oncology research; and to memorialize their
daughter.
Genetic Sites
Devoted to Brianna Diagnosed at age 9 months
with Canavan’s
Leukodystrophy; age 11 at
analysis
Informational site set up to update family, friends, and
larger online community about her status and needs; to
raise funds to cover her health care and to support
research; to advocate for research funding and access
to clinical trials; and to raise awareness about the disease
and the need for a cure.
Charley’s Fund Diagnosed at age 3 with
Duchenne Muscular
Dystrophy; age 4 at analysis
Research-focused foundation site set up to raise funds
for translational research, specifically GTR, and to raise
awareness and share information about the disease, their
experiences, and the need for research.
Hope for Henry Diagnosed at birth with
Fanconi’s Anemia; died at
age 7
Support-focused foundation site set up to raise funds
for electronic gifts to promote comfort and recovery; to
raise awareness about the disease and the need for
research funding; to advocate for bone marrow
registration and research; and as a tribute to Henry.
Parents have two affiliated blogs to chronicle their
experiences.
Bethany’s Hope Diagnosed at age 2 with
Metachromatic
Leukodystrophy
Neuroblastoma; died at age 7
Research-focused foundation site set up to raise
awareness about the disease; to advocate and raise
funding for research; to share her story to inspire others;
and to build community among affected families.
The Official Alexi
Soraya Site
Diagnosed at birth with
Osteogenesis Imperfecta; age
3-½ at analysis
Informational site set up to provide guidance about
caring for affected children (for both parents and MDs);
to advocate for parent-doctor partnerships in caring for
these children; and to update family and friends about
the children’s progress.
Rachaeli Diagnosed at age 1 with Tay
Sachs; age 3-½ at analysis
Tribute/memorial site set up to honor daughter; to
update family and friends about her status; to provide a
therapeutic outlet for Rachaeli’s father; and to share
information about the disease, related research, and the
need to raise funding for research.
Nathan’s Battle Diagnosed at age 4 with
Batten’s Disease; age 10 at
analysis
Research-focused foundation site set up to raise
funding for translational research, especially GTR; to
provide information about the disease and related
research; to update family and friends; and to advocate
for access to clinical trials.
Adriana van Merwe Diagnosed at age 5 with
SCID; died at age 7
Fundraising site set up to help her family cover her
health care costs; to share information about the
condition, treatment, and need for research funding and
bone marrow donors; and to update family and friends
on her status.
Team Mat Diagnosed at age 2 with
Cystic Fibrosis; age 11 at
analysis
Research-focused fundraising site set up to raise
awareness about fundraising efforts; to share their son’s
story; to raise awareness about the disease and the need
for research; and to explain technical information related
to the disease.
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Site Name Diagnosis and Age Function/Mission of Site
FightSMA Diagnosed at age 1 with
Spinal Muscular Atrophy;
age 20 at analysis
Research-focused foundation site set up to raise
awareness about the disease; to advocate for research
and treatment; to build a community among affected
families; and to share information about current and
future research. Includes Fighter Mom, the resource
program designed to transform parents into advocates.
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Screenshot of Alex’s Lemonade Stand’s home page, September 10, 2007
(http://www.alexslemonade.org/home). Copyright © Alex’s Lemonade Foundation.
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Screenshot of Nathan’s Battle’s home page, September 10, 2007
(http://www.nathansbattle.com/). Copyright © Nathan’s Battle Foundation.
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